{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:29:13Z","timestamp":1790742553625,"version":"4.1.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T00:00:00Z","timestamp":1557446400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.nefro.2019.03.004","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T17:57:34Z","timestamp":1560189454000},"page":"568-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["MAP3K kinases and kidney injury"],"prefix":"10.1016","volume":"39","author":[{"given":"Leticia","family":"Cuarental","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sucunza-S\u00e1enz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Vali\u00f1o-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fernandez-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Belen","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dolores","family":"Sanchez-Ni\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2019.03.004_bib0570","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nefro.2019.03.004_bib0575","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1042\/CS20160395","article-title":"Translational science in chronic kidney disease","volume":"131","author":"Sanchez-Ni\u00f1o","year":"2017","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.nefro.2019.03.004_bib0580","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1681\/ASN.2016050562","article-title":"Global cardiovascular and renal outcomes of reduced GFR","volume":"28","author":"Thomas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0585","first-page":"78","article-title":"EPIRCE Study Group Prevalence of chronic renal disease in Spain: results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrologia"},{"key":"10.1016\/j.nefro.2019.03.004_bib0590","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"390","year":"2017","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nefro.2019.03.004_bib0595","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.medcli.2018.05.011","article-title":"The burden of disease in Spain: results from the Global Burden of Disease 2016","volume":"151","author":"Soriano","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.nefro.2019.03.004_bib1135","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.nefro.2018.09.002","article-title":"The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: keeping chronic kidney disease out of sight of health authorities will only magnify the problem","volume":"39","author":"Ortiz","year":"2019","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2019.03.004_bib0605","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nrneph.2017.52","article-title":"The systemic nature of CKD","volume":"13","author":"Zoccali","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0610","first-page":"1","article-title":"A comprehensive review of protein kinase inhibitors for cancer therapy","author":"Kannaiyan","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.nefro.2019.03.004_bib0615","article-title":"Mitogen-activated protein kinase 14 promotes AKI","author":"Ortiz","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1140","article-title":"MAGE genes in the kidney: identification of MAGED2 as upregulated during kidney injury and in stressed tubular cells","author":"chak","year":"2018","journal-title":"Nephrol Dial Transplant."},{"key":"10.1016\/j.nefro.2019.03.004_bib0625","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbagen.2007.12.011","article-title":"Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling","volume":"1780","author":"Matsuzawa","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nefro.2019.03.004_bib0630","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11248-006-9052-0","article-title":"In vivo functions of mitogen-activated protein kinases: conclusions from knock-in and knock-out mice","volume":"16","author":"Gerits","year":"2007","journal-title":"Transgenic Res"},{"key":"10.1016\/j.nefro.2019.03.004_bib0635","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/35065000","article-title":"Mammalian MAP kinase signalling cascades","volume":"410","author":"Chang","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.nefro.2019.03.004_bib0640","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1111\/j.1582-4934.2009.00766.x","article-title":"Tweak induces proliferation in renal tubular epithelium: a role in uninephrectomy induced renal hyperplasia","volume":"13","author":"Sanz","year":"2009","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0645","doi-asserted-by":"crossref","first-page":"F396","DOI":"10.1152\/ajprenal.00565.2013","article-title":"Activation of ERK1\/2 by NADPH oxidase-originated reactive oxygen species mediates uric acid-induced mesangial cell proliferation","volume":"307","author":"Zhuang","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0650","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/path.4250","article-title":"TWEAK transactivation of the epidermal growth factor receptor mediates renal inflammation","volume":"231","author":"Rayego-Mateos","year":"2013","journal-title":"J Pathol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0655","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1128\/MMBR.00031-10","article-title":"Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases","volume":"75","author":"Cargnello","year":"2011","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.nefro.2019.03.004_bib0660","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3389\/fphys.2017.00829","article-title":"The JNK signaling pathway in renal fibrosis","volume":"8","author":"Grynberg","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0665","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.taap.2013.08.011","article-title":"Calcineurin inhibitors recruit protein kinases JAK2 and JNK TLR signaling and the UPR to activate NF-\u03baB-mediated inflammatory responses in kidney tubular cells","volume":"272","author":"Gonz\u00e1lez-Guerrero","year":"2013","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0670","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00204-016-1830-8","article-title":"TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity","volume":"91","author":"Gonz\u00e1lez-Guerrero","year":"2017","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0675","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12882-018-0968-4","article-title":"Angiotensin II-induced podocyte apoptosis is mediated by endoplasmic reticulum stress\/PKC-\u03b4\/p38 MAPK pathway activation and trough increased Na+\/H+ exchanger isoform 1 activity","volume":"19","author":"Cardoso","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0680","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1172\/JCI99768","article-title":"ASK1 contributes to fibrosis and dysfunction in models of kidney disease","volume":"128","author":"Liles","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nefro.2019.03.004_bib0685","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1681\/ASN.2008020194","article-title":"The MIF receptor CD74 in diabetic podocyte injury","volume":"20","author":"Sanchez-Ni\u00f1o","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0690","doi-asserted-by":"crossref","first-page":"C1089","DOI":"10.1152\/ajpcell.00387.2013","article-title":"A positive feedback loop involving Erk5 and Akt turns on mesangial cell proliferation in response to PDGF","volume":"306","author":"Bera","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0695","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3389\/fphar.2014.00071","article-title":"Erk5 is a mediator to TGF\u03b21-induced loss of phenotype and function in human podocytes","volume":"5","author":"Badshah","year":"2014","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0700","doi-asserted-by":"crossref","first-page":"6470","DOI":"10.1074\/jbc.M110.181529","article-title":"Activation loop phosphorylation of ERK3\/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3\/4-MAPK-activated protein kinase 5 signaling pathway","volume":"286","author":"D\u00e9l\u00e9ris","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefro.2019.03.004_bib0705","doi-asserted-by":"crossref","first-page":"49144","DOI":"10.18632\/oncotarget.17100","article-title":"Extracellular signal-regulated kinase 8-mediated NF-\u03baB activation increases sensitivity of human lung cancer cells to arsenic trioxide","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.nefro.2019.03.004_bib0710","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/385540a0","article-title":"MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1","volume":"385","author":"Malinin","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.nefro.2019.03.004_bib0715","first-page":"5","article-title":"TWEAK activates the non-canonical NFkB pathway in murine renal tubular cells: modulation of CCL21","author":"Sanz","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.nefro.2019.03.004_bib0720","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-\u03baB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nefro.2019.03.004_bib0725","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1126\/science.1062677","article-title":"Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway","volume":"293","author":"Senftleben","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nefro.2019.03.004_bib0730","first-page":"pt14","article-title":"SCF-mediated degradation of p100 (NF-\u03baB2): mechanisms and relevance in multiple myeloma","volume":"5","author":"Busino","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.nefro.2019.03.004_bib0735","first-page":"7","article-title":"Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases","author":"Xiong","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.nefro.2019.03.004_bib0740","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1016\/j.cub.2016.10.009","article-title":"NIK\/MAP3K14 regulates mitochondrial dynamics and trafficking to promote cell invasion","volume":"26","author":"Jung","year":"2016","journal-title":"Curr Biol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0745","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/nm.2756","article-title":"NF-\u03baB-inducing kinase (NIK) promotes hyperglycemia and glucose intolerance in obesity by augmenting glucagon action","volume":"18","author":"Sheng","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0750","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/cdd.2015.69","article-title":"NIK promotes tissue destruction independently of the alternative NF-\u03baB pathway through TNFR1\/RIP1-induced apoptosis","volume":"22","author":"Boutaffala","year":"2015","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.nefro.2019.03.004_bib0755","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1681\/ASN.2010020218","article-title":"NF-kappaB in renal inflammation","volume":"21","author":"Sanz","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0760","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfx376","article-title":"Albumin downregulates Klotho in tubular cells","author":"Fernandez-Fernandez","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nefro.2019.03.004_bib0765","doi-asserted-by":"crossref","first-page":"F1329","DOI":"10.1152\/ajprenal.00487.2016","article-title":"Downregulation of kidney protective factors by inflammation: role of transcription factors and epigenetic mechanisms","volume":"311","author":"Ruiz-Andres","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0770","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1681\/ASN.2010101073","article-title":"The inflammatory cytokines TWEAK and TNF\u03b1 reduce renal klotho expression through NF\u03baB","volume":"22","author":"Moreno","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0775","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1681\/ASN.2007050581","article-title":"The death ligand TRAIL in diabetic nephropathy","volume":"19","author":"Lorz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0780","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/ki.2015.332","article-title":"The inflammatory cytokine TWEAK decreases PGC-1\u03b1 expression and mitochondrial function in acute kidney injury","volume":"89","author":"Ruiz-Andres","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.nefro.2019.03.004_bib0785","doi-asserted-by":"crossref","DOI":"10.1002\/path.5132","article-title":"CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury","author":"Gonz\u00e1lez-Guerrero","year":"2018","journal-title":"J Pathol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0790","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.1038\/emm.2017.89","article-title":"Bcl3: a regulator of NF-\u03baB inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells","volume":"49","author":"Poveda","year":"2017","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0795","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbadis.2016.01.006","article-title":"NF\u03baBiz protein downregulation in acute kidney injury: modulation of inflammation and survival in tubular cells","volume":"1862","author":"Poveda","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nefro.2019.03.004_bib0800","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1681\/ASN.2007050577","article-title":"The cytokine TWEAK modulates renal tubulointerstitial inflammation","volume":"19","author":"Sanz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0805","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fimmu.2013.00447","article-title":"TWEAK\/Fn14 and non-canonical NF-kappaB signaling in kidney disease","volume":"4","author":"Poveda","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0810","doi-asserted-by":"crossref","first-page":"28857","DOI":"10.1038\/srep28857","article-title":"Non-canonical NF\u03baB activation promotes chemokine expression in podocytes","volume":"6","author":"Vali\u00f1o-Rivas","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.nefro.2019.03.004_bib0815","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1097\/TP.0b013e3181a1905e","article-title":"Small interfering RNA targeting RelB protects against renal ischemia-reperfusion injury","volume":"87","author":"Feng","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nefro.2019.03.004_bib0820","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1124\/mol.112.084053","article-title":"The nuclear factor \u03baB family member RelB facilitates apoptosis of renal epithelial cells caused by cisplatin\/tumor necrosis factor \u03b1 synergy by suppressing an epithelial to mesenchymal transition-like phenotypic switch","volume":"84","author":"Benedetti","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0825","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41467-017-02672-0","article-title":"NF-\u03baB inducing kinase is a therapeutic target for systemic lupus erythematosus","volume":"9","author":"Brightbill","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.nefro.2019.03.004_bib0830","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1016\/j.bbadis.2013.08.010","article-title":"Fn14 in podocytes and proteinuric kidney disease","volume":"1832","author":"Sanchez-Ni\u00f1o","year":"2013","journal-title":"Biochim Biophys Acta \u2013 Mol Basis Dis"},{"key":"10.1016\/j.nefro.2019.03.004_bib0835","doi-asserted-by":"crossref","first-page":"F75","DOI":"10.1152\/ajprenal.00398.2013","article-title":"Relevant role of PKG in the progression of fibrosis induced by TNF-like weak inducer of apoptosis","volume":"307","author":"Mart\u00edn","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0840","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.bbadis.2013.05.032","article-title":"TNF-related weak inducer of apoptosis (TWEAK) promotes kidney fibrosis and Ras-dependent proliferation of cultured renal fibroblast","volume":"1832","author":"Ucero","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nefro.2019.03.004_bib0845","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/cvr\/cvw239","article-title":"Tweak up-regulates endothelin-1 system in mouse and human endothelial cells","volume":"113","author":"Mart\u00ednez-Miguel","year":"2017","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.nefro.2019.03.004_bib0850","doi-asserted-by":"crossref","first-page":"e2305","DOI":"10.1038\/cddis.2016.220","article-title":"TWEAK favors phosphate-induced calcification of vascular smooth muscle cells through canonical and non-canonical activation of NF\u03baB","volume":"7","author":"H\u00e9naut","year":"2016","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.nefro.2019.03.004_bib0855","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14728222.2015.1081685","article-title":"Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification","volume":"20","author":"H\u00e9naut","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.nefro.2019.03.004_bib0860","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.0105-2896.2006.00375.x","article-title":"Circuitry of nuclear factor kappaB signaling","volume":"210","author":"Hoffmann","year":"2006","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nefro.2019.03.004_bib0865","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nefro.2019.03.004_bib0870","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1038\/sj.emboj.7600391","article-title":"Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers","volume":"23","author":"Bonizzi","year":"2004","journal-title":"EMBO J"},{"key":"10.1016\/j.nefro.2019.03.004_bib0875","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1126\/science.1071914","article-title":"The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation","volume":"298","author":"Hoffmann","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.nefro.2019.03.004_bib0880","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00208.2016","article-title":"ASK1: a new therapeutic target for kidney disease","volume":"311","author":"Tesch","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0885","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.bbrc.2007.10.122","article-title":"Important role of apoptosis signal-regulating kinase 1 in ischemic acute kidney injury","volume":"364","author":"Terada","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nefro.2019.03.004_bib0890","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2174\/18715257113119990085","article-title":"NQDI 1, an inhibitor of ASK1 attenuates acute ischemic renal injury by modulating oxidative stress and cell death","volume":"11","author":"El Eter","year":"2013","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.nefro.2019.03.004_bib0895","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ajpath.2011.09.017","article-title":"Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis","volume":"180","author":"Ying","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0900","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.molimm.2007.11.013","article-title":"Role of apoptosis signal-regulating kinase 1 in complement-mediated glomerular epithelial cell injury","volume":"45","author":"Ren","year":"2008","journal-title":"Mol Immunol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0905","doi-asserted-by":"crossref","first-page":"4522","DOI":"10.1111\/jcmm.13705","article-title":"ASK1 inhibitor treatment suppresses p38\/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis","volume":"22","author":"Amos","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0910","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11255-013-0520-1","article-title":"Unilateral ureteral obstruction: beyond obstruction","volume":"46","author":"Ucero","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0915","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00211.2014","article-title":"ASK1\/p38 signaling in renal tubular epithelial cells promotes renal fibrosis in the mouse obstructed kidney","volume":"307","author":"Ma","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0920","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.2337\/db15-0384","article-title":"ASK1 inhibitor halts progression of diabetic nephropathy in Nos3-deficient mice","volume":"64","author":"Tesch","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.nefro.2019.03.004_bib0925","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000369152","article-title":"Design of a phase 2 clinical trial of an ASK1 inhibitor GS-4997, in patients with diabetic kidney disease","volume":"129","author":"Lin","year":"2015","journal-title":"Nephron"},{"key":"10.1016\/j.nefro.2019.03.004_bib0930","first-page":"1","article-title":"Targeting inflammation in diabetic kidney disease: early clinical trials","author":"Perez-Gomez","year":"2016","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.nefro.2019.03.004_bib0935","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.29514","article-title":"The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial","volume":"67","author":"Loomba","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.nefro.2019.03.004_bib0940","unstructured":"https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=375685; accessed December 6, 2018 n.d."},{"key":"10.1016\/j.nefro.2019.03.004_bib0945","first-page":"537","article-title":"Serum soluble tumor necrosis factor receptor 1 (sTNFR1) associates with decline in estimated glomerular filtration rate (eGFR) slope in a phase 2 study of selonsertib in diabetic kidney disease (DKD)","volume":"29","author":"Tarrant","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0950","doi-asserted-by":"crossref","first-page":"F1410","DOI":"10.1152\/ajprenal.00018.2011","article-title":"TGF-\u03b21-activated kinase-1 regulates inflammation and fibrosis in the obstructed kidney","volume":"300","author":"Ma","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0955","first-page":"1","article-title":"TAK1 mediates apoptosis via p38 involve in ischemia-induced renal fibrosis","author":"Zhou","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0960","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1111\/jcmm.13585","article-title":"TAK1 mediates excessive autophagy via p38 and ERK in cisplatin-induced acute kidney injury","volume":"22","author":"Zhou","year":"2018","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0965","doi-asserted-by":"crossref","first-page":"F336","DOI":"10.1152\/ajprenal.00493.2017","article-title":"Inactivation of MAP3K7 in FOXD1-expressing cells results in loss of mesangial PDGFRB and juvenile kidney scarring","volume":"315","author":"Karolak","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0970","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1440-1797.2008.00959.x","article-title":"Serine\/threonine kinase Cot\/Tpl2, regulates renal cell apoptosis in ischaemia\/reperfusion injury","volume":"13","author":"Yaomura","year":"2008","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.nefro.2019.03.004_bib0975","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/ncomms2283","article-title":"ASK3 responds to osmotic stress and regulates blood pressure by suppressing WNK1-SPAK\/OSR1 signaling in the kidney","volume":"3","author":"Naguro","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.nefro.2019.03.004_bib0980","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/jcm4061325","article-title":"Horizon 2020 in diabetic kidney disease: the clinical trial pipeline for add-on therapies on top of renin angiotensin system blockade","volume":"4","author":"Perez-Gomez","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib0985","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2014.74","article-title":"Therapeutic approaches to diabetic nephropathy \u2013 beyond the RAS","volume":"10","author":"Fernandez-Fernandez","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0990","doi-asserted-by":"crossref","first-page":"321714","DOI":"10.1155\/2012\/321714","article-title":"Antioxidants in kidney diseases: the impact of bardoxolone methyl","volume":"2012","author":"Rojas-Rivera","year":"2012","journal-title":"Int J Nephrol"},{"key":"10.1016\/j.nefro.2019.03.004_bib0995","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2174\/1389450116666150416120108","article-title":"Cancer kinases and its novel inhibitors: past present and future challenges","volume":"16","author":"Pillai","year":"2015","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.nefro.2019.03.004_bib1000","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib1005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1248\/bpb.b15-00103","article-title":"Therapeutic drug monitoring of imatinib, nilotinib, and dasatinib for patients with chronic myeloid leukemia","volume":"38","author":"Miura","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.nefro.2019.03.004_bib1010","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/1060028013501144","article-title":"Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"47","author":"Shamroe","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.nefro.2019.03.004_bib1015","doi-asserted-by":"crossref","first-page":"m109","DOI":"10.1107\/S1600536810052682","article-title":"Chloridobis(1,10-phenanthroline)zinc(II) tetra-chlorido(1,10-phenan-throline)bis-muthate(III) monohydrate","volume":"67","author":"Song","year":"2010","journal-title":"Acta Crystallogr Sect E Struct Rep Online"},{"key":"10.1016\/j.nefro.2019.03.004_bib1020","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nefro.2019.03.004_bib1025","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1634\/theoncologist.2014-0154","article-title":"Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials","volume":"20","author":"Burotto","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.nefro.2019.03.004_bib1030","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1035","first-page":"3459","article-title":"Selective use of vandetanib in the treatment of thyroid cancer","volume":"9","author":"Fallahi","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.nefro.2019.03.004_bib1040","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/rheumatology\/kex489","article-title":"Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.nefro.2019.03.004_bib1045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.nefro.2019.03.004_bib1050","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/ndt\/gfx377","article-title":"JAK1\/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial","volume":"33","author":"Tuttle","year":"2018","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.nefro.2019.03.004_bib1055","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.amjmed.2008.11.025","article-title":"Renal effects of anti-angiogenesis therapy: update for the internist","volume":"122","author":"Gurevich","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib1060","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.nefro.2019.03.004_bib1065","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefro.2019.03.004_bib1070","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/jdv.12322","article-title":"Vemurafenib significantly decreases glomerular filtration rate","volume":"28","author":"Uthurriague","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1075","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/ckj\/sfv149","article-title":"Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network","volume":"9","author":"Wanchoo","year":"2016","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.nefro.2019.03.004_bib1080","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00280-016-3086-7","article-title":"New insights into renal toxicity of the B-RAF inhibitor, vemurafenib, in patients with metastatic melanoma","volume":"78","author":"Teuma","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1085","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2015.1713","article-title":"Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib","volume":"1","author":"Jhaveri","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1090","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00280-017-3300-2","article-title":"Adjunction of a MEK inhibitor to vemurafenib in the treatment of metastatic melanoma results in a 60% reduction of acute kidney injury","volume":"79","author":"Teuma","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nefro.2019.03.004_bib1095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.ajkd.2016.12.013","article-title":"BRAF signaling pathway inhibition podocyte injury, and nephrotic syndrome","volume":"70","author":"Perico","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.nefro.2019.03.004_bib1100","doi-asserted-by":"crossref","first-page":"e7196","DOI":"10.1097\/MD.0000000000007196","article-title":"Glomerulonephritis and granulomatous vasculitis in kidney as a complication of the use of BRAF and MEK inhibitors in the treatment of metastatic melanoma: a case report","volume":"96","author":"Maanaoui","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.nefro.2019.03.004_bib1105","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1136\/bmj.2.6198.1146-d","article-title":"Reversible renal failure during treatment with captopril","volume":"2","author":"Woodhouse","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.nefro.2019.03.004_bib1110","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/bmj.2.6190.612-c","article-title":"Reversible renal failure during treatment with captopril","volume":"2","author":"Collste","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.nefro.2019.03.004_bib1115","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1136\/bmj.1.6179.1680","article-title":"Reversible renal failure during treatment with captopril","volume":"1","author":"Farrow","year":"1979","journal-title":"Br Med J"},{"key":"10.1016\/j.nefro.2019.03.004_bib1120","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0140-6736(79)92303-1","article-title":"Serum-sickness-like syndrome with membranous glomerulopathy in patient on captopril","volume":"2","author":"Hoorntje","year":"1979","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.nefro.2019.03.004_bib1125","doi-asserted-by":"crossref","first-page":"38818","DOI":"10.1074\/jbc.M110.145284","article-title":"MAP\/ERK kinase kinase 1 (MEKK1) mediates transcriptional repression by interacting with polycystic kidney disease-1 (PKD1) promoter-bound p53 tumor suppressor protein","volume":"285","author":"Islam","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nefro.2019.03.004_bib1130","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1038\/srep08078","article-title":"Apoptosis signal-regulating kinase 1 promotes Ochratoxin A-induced renal cytotoxicity","volume":"5","author":"Liang","year":"2015","journal-title":"Sci Rep"}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0211699519300785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:26Z","timestamp":1759323206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0211699519300785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0211699519300785"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2019.03.004","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MAP3K kinases and kidney injury","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2019.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}